However, patients without a family history of cancer accounted for a high proportion in the groups, with the highest in the HER2-enriched group (69.4%), followed by the TNBC group (61.1%), and the lowest in the Luminal A and B groups at 53.9% and 56.3%, respectively. Here, ERBB2 is linked to cancer.